相关实验视频
Updated: Jul 4, 2025

09:26
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
Published on: May 16, 2016
35.3K
5-氨基酸通过OSCAR-PPARγ轴抑制骨关节炎
Jihee Kim1,2, Gina Ryu1, Jeongmin Seo1
1Department of Life Science, Ewha Womans University, Seoul, Republic of Korea.
Nature communications
|February 3, 2024
概括
一种抗炎药物5-氨基酸 (5-ASA) 通过结合细胞的OSCAR来意外地治疗骨关节炎 (OA). 这种新的疾病修饰性骨关节炎药物 (DMOAD) 方法可以逆转小鼠的软骨破坏和炎症.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 整形外科 整形外科 整形外科
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,没有有效的疾病修饰药物.
- 目前的治疗方法侧重于症状管理,而不是阻止疾病的进展.
研究的目的:
- 研究5-氨基酸 (5-ASA) 作为疾病修饰性骨关节炎药物 (DMOAD) 的潜力.
- 阐明5-ASA影响OA病理的机制.
主要方法:
- 使用了手术诱导的关节骨炎 (中间阴囊不稳定) 的小鼠模型.
- 与骨关节炎发作相比,在不同的时间点内进行了关节内5-ASA注射.
- 分析了软骨厚度,基因表达 (PPARγ,COX-2) 和细胞外矩阵 (ECM) 代谢.
主要成果:
- 关节内5-ASA改善了小鼠的OA进展,即使在疾病发作后给予.
- 与未经治疗的对照组相比,5-ASA治疗导致软骨变厚.
- 从机制上讲,5-ASA逆转了OSCAR介导的PPARγ抑制,抑制了COX-2炎症,改善了体生成,并调节了ECM周转.
结论:
- 5-氨基酸 (5-ASA) 显示出作为一种新型 DMOAD 的巨大潜力.
- 5-ASA的治疗作用包括调节状细胞基因表达和ECM平衡.
- 用5-ASA准OSCAR-chondrocyte通路为骨关节炎提供了一个新的治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K

